May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Safety and effectiveness by using intravitreal solution AL027 to clear induced vitreous hemorrhage in rabbit eye
Author Affiliations & Notes
  • J.R. Gonzalez
    Medical Direction,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • V. Sanchez–Castellanos
    Medical Direction,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • L. Baiza–Duran
    Medical Direction,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • J.D. Quintana–Hau
    Research and Development,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • M.I. Lopez–Sanchez
    Research and Development,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • R. Tornero–Montaño
    Medical Direction,
    Laboratorios Sophia SA DE CV, Guadalajara, Mexico
  • Footnotes
    Commercial Relationships  J.R. Gonzalez, Laboratorios Sophia SA de CV E; V. Sanchez–Castellanos, Laboratorios Sophia SA de CV E; L. Baiza–Duran, Laboratorios Sophia SA de CV E; J.D. Quintana–Hau, l E; M.I. Lopez–Sanchez, Laboratorios Sophia SA de CV E; R. Tornero–Montaño, Laboratorios Sophia SA de CV E.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1949. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.R. Gonzalez, V. Sanchez–Castellanos, L. Baiza–Duran, J.D. Quintana–Hau, M.I. Lopez–Sanchez, R. Tornero–Montaño; Safety and effectiveness by using intravitreal solution AL027 to clear induced vitreous hemorrhage in rabbit eye . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1949.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: The objective of this study was to evaluate the safety and efficacy of an intravitreal solution AL027 (Mexican patent PCT/MX03/00093) injected to clear induced vitreous hemorrhage in New Zealand rabbit eye. Methods: Blood was extracted from rabbit marginal ear vein in twenty–six animals. The model for vitreous hemorrhage was induced by injecting 50 µL of autologous blood into vitreous through the pars plana. After seven days, severe vitreous hemorrhage was corroborated by indirect ophthalmoscopy in all injected eyes. Then, twenty–two rabbits received intravitreal injection of 50 µL of AL027 solution and four of them received the placebo. The study was followed for 3 months after AL027 injection. The following ophthalmic examination were conducted and recorded: Ocular External Eye Examination, Indirect Ophthalmoscopy on 0, 1, 7, 21, 38, 53 and 83 days. In six of them, we performed Electroretinography (ERG) and Echography at days 0 and 90. Results: At 7TH day after blood injection, all rabbit eyes presented a 2.7 mean value of vitreous hemorrhage (3 means severe vitreous hemorrhage). At 60th day after AL027 injection, the group presented a value of 1.0 of vitreous hemorrhage and after 83 days, total clearance of the vitreous hemorrhage was observed, (vitreous hemorrhage mean of 0). For placebo group, vitreous hemorrhage value was 2.7 at day 45, and 2.3 both 60 and 90 days. Data from ERG and Echography studies shown than in only one rabbit from the test group presented retinal detachment, probably due to the injection procedure. Other abnormalities were not found in the subject rabbit eyes. Conclusions: These results suggest that intravitreal solution AL027 injected into rabbit model for vitreous hemorrhage induced a progressive clearance. Injection of AL027 and placebo were safe, because no anatomical alterations were found.

Keywords: vitreous • proliferative vitreoretinopathy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×